Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $144.76M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.24M
Average 0.28M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Sutro Biopharma, Inc.
NASDAQ:STRO
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +14.8% | -5.6% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +14.8% over three years. Forward estimates point to Revenue at -5.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | $4.65 | Not rated | -10.9 | +132.14% |
Precision BioSciences, Inc. NASDAQ:DTIL | $211.33M | $7.57 | Not rated | -1.9 | +43.36% |
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $198.22M | $4.01 | Not rated | -2.7 | +12.98% |
InflaRx N.V. NASDAQ:IFRX | $172.42M | $1.17 | Not rated | -2.7 | -13.49% |
Pliant Therapeutics, Inc. NASDAQ:PLRX | $43.16M | $0.70 | Not rated | -0.6 | -46.02% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $42.65M | $0.68 | Not rated | -4.0 | -74.53% |
Kalaris Therapeutics Inc NASDAQ:KLRS | $37.49M | $1.58 | Not rated | -2.5 | -65.57% |
Fractyl Health, Inc. Common Stock NASDAQ:GUTS | $11.99M | $0.90 | Not rated | -0.6 | +212.78% |
Continue the stock analysis
Jump to another research area for this company.